Huadong Medicine's Subsidiary Daoer Biotech Receives IND Approval for Class 1 New Drug DR30303 in China

On January 20, Huadong Medicine Co., Ltd. announced thatHuadong Medicine HoldingsThe subsidiary Doer Biologics on 1August 18Received nationwide《Drug Clinical Trial Approval Notice》 issued by the National Medical Products Administration(Notice No.: 2022LP00075), a Class 1 new biological product applied by Doer BiologicsThe Phase I Clinical Trial Application for DR30303 Injection Has Been Approved, Aiming to Evaluate HumanizedSafety and Tolerability of Claudin18.2 Monoclonal Antibody-DR30303 in the Treatment of Advanced Solid TumorsPharmacokinetics and Preliminary Efficacy.